Seòmar agus comataidhean

NHS boards have advised my officials that they have completed their review of patient records and this has confirmed that no PIP silicone breast implants have been used by NHSScotland.

The question of whether or not breast implants are used by NHSScotland on women and the kind of implant to be used are clinical issues managed by NHS boards.

Information is not held centrally in the form requested.

All adverse incidents reported to the Incident Reporting and Investigation Centre (IRIC) of National Services Scotland are reviewed and, where appropriate, an in depth investigation into the cause undertaken. Adverse incidents can arise from a number of causes which include either a failure or fault with a medical device, incorrect use or issues with the packaging, storage or instructions for use.

Information from both adverse incident reports and investigations is shared with the Medical and Healthcare products Regulatory Authority (MHRA) who assess the most appropriate form of remedial action including issuing a medical device alert, or discussions the manufacturer and issue of a Field Safety Notice.

I refer the member to the answer to question S4W-05274 on 7 February 2012. All answers to written parliamentary questions are available on the Parliament’s website, the search facility for which can be found at:

http://www.scottish.parliament.uk/parliamentarybusiness/28877.aspx.

There is currently an MCN for Chronic Pain operating in NHS Greater Glasgow and Clyde.

In addition, Chronic Pain Service Improvement Groups have been established in NHS Fife and NHS Lanarkshire and we continue to encourage NHS boards to establish service improvement groups or MCNs for chronic pain.

I refer the member to the answer to question S4W-05274 on 7 February 2012. All answers to written parliamentary questions are available on the Parliament’s website, the search facility for which can be found at:

http://www.scottish.parliament.uk/parliamentarybusiness/28877.aspx.

The Cabinet Secretary for Health, Wellbeing and Cities Strategy has not met representatives from these private healthcare providers. At the request of the provider, Scottish Government officials are scheduled to meet with representatives of Transform on 9 February 2012.

The cost of sending patients with chronic pain to pain management centre’s outside Scotland was:

(a) 2008-09 - £229,559

(b) 2009-10 - £201,347

(c) 2010-11 - £313,339

(d) 2011-12 to 09-01-12 - 231,757.

These costs are shared across all NHS boards as part of the national risk share arrangements administered by National Services Division. Boards’ contribution is calculated on their percentage share of the baseline allocation.

As a result of late presentation and/or invoice queries, figures can be subject to change. The total cost for 2009-10 provided in the table updates the figure of £184,937 provided in answer to question S3W-37826 on 10 December 2010.

All answers to written parliamentary questions are available on the Parliament’s website, the search facility for which can be found at:

http://www.scottish.parliament.uk/parliamentarybusiness/28877.aspx.

A scoping exercise of pain management services in Scotland has been carried out by Healthcare Improvement Scotland and our lead clinician on chronic pain, which has gathered information on the resources available in each NHS board.

Analysis and verification of the findings is under way and a report is expected to be completed by the end of March 2012.

The information requested is not held centrally.